Vascular surgery

InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021

Retrieved on: 
Friday, May 14, 2021
Medical specialties, Neurosurgery, Vascular surgery, Finance, Carotid artery stenosis, Carotid stenting, Clinical medicine, Stroke, Ticker symbol, New York Stock Exchange, Carotid artery

b'TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Investor Summit Conference on May 17, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:00am ET on May 17, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

Key Points: 
  • b'TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Investor Summit Conference on May 17, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:00am ET on May 17, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

Gregory A. Crooke, MD is recognized by Continental Who's Who

Retrieved on: 
Thursday, May 13, 2021
Medical specialties, Surgery, Clinical medicine, Surgical specialties, Cardiac surgery, Vascular surgery, Cardiothoracic surgery

The state-of-the-art cardiovascular institute is located in Borough Park and easily accessible from Park Slope, Dyker Heights, and Sunset Park.

Key Points: 
  • The state-of-the-art cardiovascular institute is located in Borough Park and easily accessible from Park Slope, Dyker Heights, and Sunset Park.
  • In a collaborative setting, the highly trained and dedicated cardiologists, cardiothoracic, and vascular surgeons perform thousands of non-invasive, minimally invasive, and interventional procedures every year.
  • He is widely recognized for demonstrating the highest level of professionalism and integrity and is the recipient of the Castle Connelly Award, and the Paul Harris Rotary Award.
  • Crooke dedicates this honorable recognition to Dr. Stearns, Dr. Greg H. Ribakove, and Dr. Steven Coleman.\n"

Insights on the Varicose Vein Treatments Global Market to 2026 - Players Include Boston Scientific, Candela Medical and Medtronic Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 11, 2021
Surgery, Health, Medical devices, Vascular surgery, Varicose veins, Economy, Market share analysis, Fundamental analysis, Product pipeline, Microeconomics, Market economics)

b'The format of this study includes:\nDetailed descriptions of the disease including classification, anatomy, pathophysiology and risk factors.\nDetailed market projections through 2026.\nKey marketed products along with information about their regulatory status.\nDiscussions about the future of varicose vein treatments.\nAnalyses of the global market trends, with data from 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026\nEstimation of the current market size and market forecast for varicose veins treatment, and corresponding market share analysis by product type, end user and geographic region\nEvaluation of the impact of demographic, economic, and other factors that will drive future demand for the market\nHighlights of current and future market potential of generic drugs along with a detailed review of technology updates, regulatory scenario and product pipeline analysis within the marketplace\n'

Key Points: 
  • b'The format of this study includes:\nDetailed descriptions of the disease including classification, anatomy, pathophysiology and risk factors.\nDetailed market projections through 2026.\nKey marketed products along with information about their regulatory status.\nDiscussions about the future of varicose vein treatments.\nAnalyses of the global market trends, with data from 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026\nEstimation of the current market size and market forecast for varicose veins treatment, and corresponding market share analysis by product type, end user and geographic region\nEvaluation of the impact of demographic, economic, and other factors that will drive future demand for the market\nHighlights of current and future market potential of generic drugs along with a detailed review of technology updates, regulatory scenario and product pipeline analysis within the marketplace\n'

Endologix LLC Announces Launch of ALTO® Abdominal Stent Graft System in Canada and Argentina

Retrieved on: 
Tuesday, May 11, 2021
Health, Surgery, Cardiology, Medical devices, Interventional radiology, Medical specialties, Vascular surgery, Medicine, Endovascular aneurysm repair, Clinical medicine, Evar, Stent, XC2, Abdominal Aortic Aneurysm (AAA), the ALTO Abdominal Stent Graft System, Endologix’s Product Portfolio, Endologix, ABDOMINAL AORTIC ANEURYSM (AAA), THE ALTO ABDOMINAL STENT GRAFT SYSTEM, ENDOLOGIX’S PRODUCT PORTFOLIO, ENDOLOGIX

b"Endologix LLC , a leader in the treatment of vascular disease, today announced the first implant of its ALTO\xc2\xae Abdominal Stent Graft in Canada following recent approval from Health Canada.

Key Points: 
  • b"Endologix LLC , a leader in the treatment of vascular disease, today announced the first implant of its ALTO\xc2\xae Abdominal Stent Graft in Canada following recent approval from Health Canada.
  • View the full release here: https://www.businesswire.com/news/home/20210511005366/en/\nFeaturing a unique, patented, sealing technology, the ALTO Abdominal Stent Graft System is the latest generation in polymer-based therapies for AAA patients.
  • ALTO utilizes a low-profile delivery system and, unlike standard EVAR devices, features an exclusive conformable sealing ring that molds in-situ to the patient\xe2\x80\x99s specific aortic neck anatomy.
  • The company\xe2\x80\x99s current commercial EVAR products include the AFX\xc2\xae2 device and the ALTO\xc2\xae Abdominal Stent Graft System.

InspireMD to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021

Retrieved on: 
Thursday, May 6, 2021
Medical specialties, Neurosurgery, Vascular surgery, Carotid artery stenosis, Carotid stenting, Clinical medicine, Medicine, Stroke, Carotid artery

b'TEL AVIV, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:10am ET on May 14, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInvestors can register for the conference here:\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

Key Points: 
  • b'TEL AVIV, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard\xe2\x84\xa2 Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), announced today that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.\nChief Executive Officer Marvin Slosman will deliver his corporate presentation at 11:10am ET on May 14, 2021.\nInvestors can also request a one-on-one meeting with Mr. Slosman to be arranged following the conclusion of the conference.\nInvestors can register for the conference here:\nInspireMD seeks to utilize its proprietary MicroNet\xc2\xae technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.\nInspireMD\xe2\x80\x99s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS and NSPR.WSB.\n'

Silk Road Medical to Present at BofA Securities 2021 Virtual Health Care Conference

TCAR, Vascular diseases, Vascular surgery, Carotid artery stenosis, Stroke, Revascularization, Silkroad, Medicine

b'SUNNYVALE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the upcoming BofA Securities 2021 Virtual Health Care Conference.\nSilk Road Medical\xe2\x80\x99s management is scheduled to present on Wednesday, May 12, 2021 at 11:00 a.m. Eastern Time.

Key Points: 
  • b'SUNNYVALE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the upcoming BofA Securities 2021 Virtual Health Care Conference.\nSilk Road Medical\xe2\x80\x99s management is scheduled to present on Wednesday, May 12, 2021 at 11:00 a.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the presentation on the \xe2\x80\x9cInvestors\xe2\x80\x9d section of the company\xe2\x80\x99s website at: https://investors.silkroadmed.com/ .\nSilk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact.
  • The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR).
  • For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter , LinkedIn and Facebook .\n'

Vascular Therapies Announces Clinical Results From Its Phase 3 Randomized Multicenter Clinical Trial

Retrieved on: 
Thursday, April 29, 2021
Health, Surgery, Clinical trials, General Health, Pharmaceutical, Biotechnology, Health sciences, Health, Medical specialties, Nephrology, Clinical trial, Vascular surgery, Kidney, Chronic Kidney Disease, Hemodialysis and Vascular Access, Vascular Therapies, CHRONIC KIDNEY DISEASE, HEMODIALYSIS AND VASCULAR ACCESS, VASCULAR THERAPIES

Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen\xe2\x84\xa2 showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.\nFollowing positive clinical results from a Phase 2 clinical study (n=30; 2 international sites, 2 surgeons), the company embarked on the ACCESS study, a Phase 3 U.S. randomized, controlled, multicenter clinical trial.

Key Points: 
  • Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen\xe2\x84\xa2 showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.\nFollowing positive clinical results from a Phase 2 clinical study (n=30; 2 international sites, 2 surgeons), the company embarked on the ACCESS study, a Phase 3 U.S. randomized, controlled, multicenter clinical trial.
  • The ACCESS study enrolled 243 patients with end stage renal disease (\xe2\x80\x9cESRD\xe2\x80\x9d) and chronic kidney disease (\xe2\x80\x9cCKD\xe2\x80\x9d) from 20 U.S. sites, including 20 nephrologists and 26 surgeons.
  • We would like to thank the nephrologists, surgeons, clinical coordinators and patients for their participation in the study.\xe2\x80\x9d\nJohn McDermott, Chief Executive Officer of Vascular Therapies commented, \xe2\x80\x9cWe are pleased with several positive clinical findings from the ACCESS study and are collaborating with the FDA to design another clinical trial to validate the results.
  • The goal of this therapeutic approach is to improve vascular surgery outcomes in patients with kidney and vascular diseases.

First Super-Hybrid Ambulatory Surgical Center Opens in Southern California

Retrieved on: 
Thursday, April 29, 2021
Outpatient surgery, Surgery, Ambulatory care, Vascular surgery

Dr. Hewett pioneered the super-hybrid ambulatory surgical model, offering the most comprehensive outpatient vascular surgical services within Orange County, and representing a transformative vision for the future of ambulatory surgery.

Key Points: 
  • Dr. Hewett pioneered the super-hybrid ambulatory surgical model, offering the most comprehensive outpatient vascular surgical services within Orange County, and representing a transformative vision for the future of ambulatory surgery.
  • Orange County Surgical Center is the only Medicare-certified, super-hybrid ambulatory surgical center in Orange County.
  • Now, Dr. Hewett has put his extensive experience and expertise to work building Orange County Surgical Center, the most advanced outpatient surgical center ever constructed in Orange County.\nAccording to Dr. Hewett, "Orange County Surgical Center represents the future of healthcare.
  • This super-hybrid ambulatory surgical center combines the best of the vascular physician\'s office, vascular diagnostic imaging, outpatient endovascular procedures, and the most advanced ambulatory surgical care available.\nOrange County Surgical Center uses the latest advancements in the delivery of outpatient vascular and dialysis care.

Prominent Albuquerque Practice Joins Center For Vein Restoration

Retrieved on: 
Thursday, April 29, 2021
Medical specialties, Angiology, Medicine, Vascular surgery, Veins, Varicose veins, Telangiectasia, Edema, Harding

b'GREENBELT, Md., April 29, 2021 /PRNewswire-PRWeb/ -- Center for Vein Restoration (CVR), the national leader in treating varicose and spider veins, has announced a new partnership with Dr. Michael Harding of Vein Center of New Mexico.

Key Points: 
  • b'GREENBELT, Md., April 29, 2021 /PRNewswire-PRWeb/ -- Center for Vein Restoration (CVR), the national leader in treating varicose and spider veins, has announced a new partnership with Dr. Michael Harding of Vein Center of New Mexico.
  • This location in Albuquerque, New Mexico, adds to our growing footprint of over 100 centers nationwide.\nDr.
  • "CVR is excited to continue expanding its reach nationwide with exceptional physicians, such as Dr. Harding," he continued.\nDr.
  • As a cardiologist, Dr. Harding prides himself on bringing a holistic approach to patients presenting with lower extremity edema and leg discomfort.

LeMaitre to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, April 27, 2021
Medical specialties, Medicine, LeMaitre Vascular, Vascular diseases, Vascular surgery, Lemaitre, Medical technology, Vascular disease, Implant, Medical specialties, Medicine, LeMaitre Vascular, Vascular diseases, Vascular surgery, Lemaitre, Medical technology, Vascular disease, Implant, Medical specialties, Medicine, LeMaitre Vascular, Vascular diseases, Vascular surgery, Lemaitre, Medical technology, Vascular disease, Implant, Medical specialties, Medicine, LeMaitre Vascular, Vascular diseases, Vascular surgery, Lemaitre, Medical technology, Vascular disease, Implant

b'BURLINGTON, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two investor conferences in May.\nDavid Roberts, President, is scheduled to participate in the 7th Annual Truist Securities Life Sciences Summit on Tuesday, May 4, 2021.\nHe is also scheduled to present at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021, at 9:00 AM EDT.\nLeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide.

Key Points: 
  • b'BURLINGTON, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two investor conferences in May.\nDavid Roberts, President, is scheduled to participate in the 7th Annual Truist Securities Life Sciences Summit on Tuesday, May 4, 2021.\nHe is also scheduled to present at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021, at 9:00 AM EDT.\nLeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide.
  • The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.
  • Additional information can be found at www.lemaitre.com.\n'